Search

Displaying results 961 - 970 of 3917 in total
  1. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

  2. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]

  3. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    This approval is based on the positive results obtained from 2 phase 3 clinical trials GATHER1 and GATHER2.[L47701] … [A260801] Avacincaptag pegol was approved by the FDA on August 4, 2023, under the brand name IZERVAY for the treatment of GA secondary to AMD.

  4. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.

  5. Drug

    Potassium citrate

    go.drugbank.com/drugs/DB09125
    ApprovedInvestigationalVet approved

    Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it...

    Mixtures: PEDIALYTE 45 MEQ CON ZINC, PEDIALYTE®30MEQ CON ZN
  6. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    L-threonate is an active metabolite of vitamin C that mediates a stimulatory action on vitamin C uptake [A27266]. … Therapeutic efficacy of calcium threonate in reducing was studied and investigated due to the hypothesis that it may play a role in the mineralization process through its positive action on vitamin C.

  7. Drug

    Mechlorethamine

    go.drugbank.com/drugs/DB00888
    ApprovedInvestigational

    It causes severe gastrointestinal and bone marrow damage. … The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL

    Categories: Chemical Warfare Agents
  8. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older.

  9. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  10. Drug

    Prednisolone acetate

    go.drugbank.com/drugs/DB15566
    ApprovedInvestigationalVet approved

    Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]